ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
HKD 4.99
(2.89%)
HKD 4.99
(2.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -355.35 Million CNY | 13.88% |
| 2022 | -384.49 Million CNY | 46.69% |
| 2021 | -718.88 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -77.33 Million HKD | 61.86% |
| 2024 Q2 | -76.67 Million HKD | 0.15% |
| 2023 Q4 | -206.81 Million HKD | -102.85% |
| 2023 FY | - CNY | 13.88% |
| 2023 Q3 | -101.95 Million HKD | 42.93% |
| 2023 Q2 | -178.65 Million HKD | -92.94% |
| 2023 Q1 | -92.59 Million HKD | 58.32% |
| 2022 FY | - CNY | 46.69% |
| 2022 Q4 | -222.14 Million HKD | -105.46% |
| 2022 Q3 | -108.12 Million HKD | 41.86% |
| 2022 Q2 | -185.96 Million HKD | 0.0% |
| 2021 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 489.495% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 172.998% |